Paul M.P. van Bergen en Henegouwen

ORCID: 0000-0001-6050-9042
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Monoclonal and Polyclonal Antibodies Research
  • HER2/EGFR in Cancer Research
  • Glycosylation and Glycoproteins Research
  • Cell Adhesion Molecules Research
  • Advanced Biosensing Techniques and Applications
  • Cellular transport and secretion
  • Lung Cancer Treatments and Mutations
  • Cytokine Signaling Pathways and Interactions
  • Nanoplatforms for cancer theranostics
  • Photodynamic Therapy Research Studies
  • Nanoparticle-Based Drug Delivery
  • Protein Kinase Regulation and GTPase Signaling
  • Immunotherapy and Immune Responses
  • Advanced Fluorescence Microscopy Techniques
  • Lipid Membrane Structure and Behavior
  • Caveolin-1 and cellular processes
  • Heat shock proteins research
  • Ubiquitin and proteasome pathways
  • Advanced biosensing and bioanalysis techniques
  • Cancer, Hypoxia, and Metabolism
  • Radiopharmaceutical Chemistry and Applications
  • Cellular Mechanics and Interactions
  • Immune Cell Function and Interaction
  • CAR-T cell therapy research
  • Advanced Electron Microscopy Techniques and Applications

Utrecht University
2015-2025

Erasmus MC Cancer Institute
2024

University Medical Center Utrecht
2012

Radboud University Nijmegen
1999

Molecular Oncology (United States)
1997

Hubrecht Institute for Developmental Biology and Stem Cell Research
1989-1997

Rockefeller University
1997

Institute of Cytology
1995

Abstract The epidermal growth factor receptor (EGFR) has been shown to be a valid cancer target for antibody‐based therapy. At present, several anti‐EGFR monoclonal antibodies have successfully used, such as cetuximab and matuzumab. X‐ray crystallography data show that these bind different epitopes on the ecto‐domain of EGFR, providing rationale combined use two antibody specificities. We previously reported successful isolation antagonistic nanobodies. In our study, we aimed improve...

10.1002/ijc.26145 article EN International Journal of Cancer 2011-04-25

The use of antibody-based therapeutics has proven very promising for clinical applications in cancer patients, with multiple examples antibodies and antibody-drug conjugates successfully applied the treatment solid tumors lymphomas. Given reported recurrence rates, improvements are clearly still necessary. A major factor limiting efficacy antibody-targeted therapies may be incomplete penetration antibody or conjugate into tumor. Incomplete tumor also affects outcome molecular imaging, when...

10.3389/fimmu.2017.01287 article EN cc-by Frontiers in Immunology 2017-10-12

Microtubules are hollow biopolymers of 25-nm diameter and key constituents the cytoskeleton. In neurons, microtubules organized differently between axons dendrites, but their precise organization in different compartments is not completely understood. Super-resolution microscopy techniques can detect specific structures at an increased resolution, narrow spacing neuronal poses challenges because most existing labelling strategies increase effective microtubule by 20-40 nm will thereby blend...

10.1038/ncomms8933 article EN cc-by Nature Communications 2015-08-11

Several enzymes involved in the phosphoinositide metabolism have been shown to be present nuclei of rat liver and Friend cells. In this paper we demonstrate that nuclear matrices mouse NIH 3T3-fibroblasts cells, isolated by nuclease treatment high salt extraction, contain phosphatidylinositol 4-kinase (PdtIns 4-kinase), 4-phosphate 5-kinase (PtdIns(4)P 5-kinase), diacylglycerol kinase, phospholipase C. By a selective extraction nucleus can dissected peripheral matrix (lamina-pore complex)...

10.1016/s0021-9258(18)42732-9 article EN cc-by Journal of Biological Chemistry 1992-03-01

In a number of recent studies it has been shown that in vivo part the EGF receptor (EGFR) population is associated to actin filament system. this paper we demonstrate purified EGFR can be cosedimented with filamentous (F-actin) indicating direct association between and actin. A truncated EGFR, previously not cytoskeleton, was used as control did cosediment filaments. Determination actin-binding domain done by measuring competition either polyclonal antibody or synthetic peptides on...

10.1083/jcb.119.2.349 article EN The Journal of Cell Biology 1992-10-15

In this paper we demonstrate that cytoskeletons isolated from A431 cells have associated with them high activities of several kinases involved in inositol lipid metabolism, such as phosphatidylinositol kinase, phosphate and diacylglycerol kinase. addition also phospholipase C activity was detected on cytoskeletons. Controlled extraction the followed by vitro polymerization actin demonstrated an association to filament system consisting a number actin-binding proteins. The...

10.1083/jcb.115.1.121 article EN The Journal of Cell Biology 1991-10-01

Many cell types display two classes of epidermal growth factor receptor (EGFR) as judged from EGF binding studies; i.e., a major class low affinity EGFR and minor high EGFR. We have studied their respective contribution to the cascade events elicited by in human A431 carcinoma cells, using anti-EGFR mAb 2E9. This antibody specifically blocks EGFR, without activating receptors intact thus enables us study effects exclusive show that blocking 2E9 has almost no effect on activation...

10.1083/jcb.109.5.2495 article EN The Journal of Cell Biology 1989-11-01

Antibodies against receptors that undergo transcytosis across the blood-brain barrier (BBB) have been used as vectors to target drugs or therapeutic peptides into brain. We recently discovered a novel single domain antibody, FC5, which transmigrates human cerebral endothelial cells in vitro and BBB vivo. The purpose of this study was characterize mechanisms FC5 endocytosis its putative receptor on brain cells. transport polarized, charge independent temperature dependent, suggesting...

10.1111/j.1471-4159.2005.03463.x article EN Journal of Neurochemistry 2005-09-16

Given that overexpression of the epidermal growth factor receptor (EGFR) is found in many types human epithelial cancers, noninvasive molecular imaging this great interest. A number studies have employed monoclonal antibodies as probes; however, their characteristic long half-life bloodstream has encouraged development smaller probes. In study, an anti-EGFR nanobody-based probe was developed and tested comparison with cetuximab for application optical imaging. To aim, nanobody 7D12 were...

10.2310/7290.2011.00025 article EN cc-by-nc Molecular Imaging 2012-01-01

Photodynamic therapy (PDT) induces cell death through local light activation of a photosensitizer (PS) and has been used to treat head neck cancers. Yet, common PS lack tumor specificity, which leads collateral damage normal tissues. Targeted delivery via antibodies pre-clinically improved selectivity. However, have long half-lives relatively poor tissue penetration, could limit therapeutic efficacy lead photosensitivity. Here, in this feasibility study, we evaluate at the pre-clinical level...

10.1016/j.jconrel.2016.03.014 article EN cc-by-nc-nd Journal of Controlled Release 2016-03-15

The suggestion that microdomains may function as signaling platforms arose from the presence of growth factor receptors, such EGFR, in biochemically isolated lipid raft fractions. To investigate role EGFR activation organization rafts we have performed FLIM analyses using putative markers ganglioside GM1 and glycosylphosphatidylinositol (GPI)-anchored GFP (GPI-GFP). was labeled single domain antibodies Llama glama specifically bind without stimulating its kinase activity. Our demonstrate a...

10.1242/jcs.028753 article EN cc-by Journal of Cell Science 2008-07-16
Coming Soon ...